

**Amendments to the Claims**

**Listing of the Claims:**

This Listing of the Claims will replace all prior versions, and listings of the claims in the application.

1-99 (canceled).

100. (original) A hapten-carrier conjugate comprising at least one hapten derived from nicotine and at least one carrier containing a T cell epitope and wherein said hapten and said carrier are linked by a branch selected from the group of chemical moieties identified by CJ reference number consisting of:

CJ 0	Q
CJ 1	$(\text{CH}_2)_n\text{Q}$
CJ 1.1	$\text{CO}_2\text{Q}$
CJ 1.2	$\text{COQ}$
CJ 1.3	$\text{OCH}_3$
CJ 2	$\text{OCO}(\text{CH}_2)_n\text{Q}$
CJ 2.1	$\text{OCOCH}=\text{Q}$
CJ 2.2	$\text{OCOCH}(\text{O})\text{CH}_2$
CJ 2.3	$\text{OCO}(\text{CH}_2)_n\text{CH}(\text{O})\text{CH}_2$
CJ 3	$\text{CO}(\text{CH}_2)_n\text{COQ}$
CJ 3.1	$\text{CO}(\text{CH}_2)_n\text{CNQ}$
CJ 4	$\text{OCO}(\text{CH}_2)_n\text{COQ}$
CJ 4.1	$\text{OCO}(\text{CH}_2)_n\text{CNQ}$
CJ 5	$\text{CH}_2\text{OCO}(\text{CH}_2)_n\text{COQ}$
CJ 5.1	$\text{CH}_2\text{OCO}(\text{CH}_2)_n\text{CNQ}$
CJ 6	$\text{CONH}(\text{CH}_2)_n\text{Q}$
CJ 7	$\text{Y}(\text{CH}_2)_n\text{Q}$
CJ 7.1	$\text{CH}_2\text{Y}(\text{CH}_2)_n\text{Q}$
CJ 8	$\text{OCOCH}(\text{OH})\text{CH}_2\text{Q}$
CJ 8.1	$\text{OCO}(\text{CH}_2)_n\text{CH}(\text{OH})\text{CH}_2\text{Q}$
CJ 9	$\text{OCOC}_6\text{H}_5$
CJ 10	as identified in the application as FIG. 1b
CJ 11	$\text{YCO}(\text{CH}_2)_n\text{COQ}$ ;

and wherein n is an integer, and Q is the carrier.

101. (amended) ~~A~~The hapten-carrier conjugate ~~according to~~ of claim 100, wherein n is from about 2 to about 20.

102. (amended) A ~~The~~ The hapten-carrier conjugate ~~according to~~ of claim 100, wherein Y is selected from the group consisting of S, O and NH.

103. (amended) A ~~The~~ The hapten-carrier conjugate ~~according to~~ of claim 100, wherein ~~the~~ said carrier is selected from: proteins or peptides, bacterial toxins or products, subvirals, lectins, allergens and fragments of allergens, malarial protein antigen, artificial multi-antigenic peptides, and modifications, analogs and derivatives thereof.

104. (original) The hapten-carrier conjugate of claim 100, wherein greater than one hapten is coupled to the carrier.

105. (canceled).

106. (canceled).

107. (canceled).

108. (canceled).

109. (amended) A pharmaceutical preparation ~~which comprises (a)~~ comprising the hapten-carrier conjugate of claim ~~105~~100, and ~~also (b) adjuvant~~ a pharmaceutically acceptable excipient.

110. (canceled).

111. (new) The hapten-carrier conjugate of claim 101, wherein said carrier is proteins or peptides, bacterial toxins or products, subvirals, lectins, allergens and fragments

of allergens, malarial protein antigen, artificial multi-antigenic peptides, and modifications, analogs and derivatives thereof.

112. (new) The hapten-carrier conjugate of claim 100, wherein said carrier is cholera toxin B, diphtheria toxin, tetanus toxoid, pertussis toxin, filamentous hemagglutinin, Shiga toxin, pseudomonas exotoxin, ricin B subunit, abrin, sweet pea lectin, retrovirus nucleoprotein, rabies nucleoprotein, tobacco mosaic virus, cauliflower mosaic virus, vesicular stomatitis virus-nucleocapsid protein, poxvirus subunit, Semliki forest virus vector or yeast virus-like particle.

113. (new) The hapten-carrier conjugate of claim 101, wherein the carrier is cholera toxin B, diphtheria toxin, tetanus toxoid, pertussis toxin, filamentous hemagglutinin, Shiga toxin, pseudomonas exotoxin, ricin B subunit, abrin, sweet pea lectin, retrovirus nucleoprotein, rabies nucleoprotein, tobacco mosaic virus, cauliflower mosaic virus, vesicular stomatitis virus-nucleocapsid protein, poxvirus subunit, Semliki forest virus vector or yeast virus-like particle.

114. (new) The hapten-carrier conjugate of claim 100, wherein said hapten derived from nicotine has the structure of nicotine or one of the nicotine metabolites depicted in Fig. 19.

115. (new) The hapten-carrier conjugate of claim 111, wherein said hapten derived from nicotine has the structure of nicotine or one of the nicotine metabolites depicted in Fig. 19.

116. (new) The hapten-carrier conjugate of claim 113, wherein said hapten derived from nicotine has the structure of nicotine or one of the nicotine metabolites depicted in Fig. 19.

117. (new) The pharmaceutical preparation of claim 109 further comprising an adjuvant.

118. (new) The pharmaceutical preparation of claim 117, wherein the adjuvant is alum, MF59 or R1B1 adjuvant.

119. (new) The pharmaceutical preparation of claim 118, wherein the alum is aluminum hydroxide or aluminum phosphate.

120. (new) The pharmaceutical preparation of claim 109 further comprising an auxiliary agent or supplementary active compound.

121. (new) The pharmaceutical preparation of claim 109 which is suitable for parenteral administration to a human.

122. (new) The pharmaceutical preparation of claim 109 which is suitable for oral, dermal or topical administration to a human.

123. (new) A pharmaceutical preparation comprising the hapten-carrier conjugate of claim 112, and a pharmaceutically acceptable excipient.

124. (new) The pharmaceutical preparation of claim 123 further comprising an adjuvant.